Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID-19 severe or critically meta-analysis

REMAP-CAP (tocilizumab)
  NCT02735707		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
353/402 conclusif -27% demonstrated58%
Talaschian
  IRCT20081027001411N4		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive 23%
Veiga
  NCT04403685		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
65/64 safety concern safety concern153% 49%
CORIMUNO-TOCI-1 (Group 1)
  NCT04331808		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
64/67 inconclusive -7% -39%
CORIMUNO-TOCI-ICU (Group 2)
  NCT04331808		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
49/43 inconclusive -32%
1 study excluded by filtering options (1 RCT / 0 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons